Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

18:07 EDT 19th April 2014 | BioPortfolio

Summary

The purpose of this study is to determine if new formulations (11.25 and 30 mg) of leuprolide are effective in treating children with Central Precocious Puberty.

Description

Study Design:

Approximately 80 children with confirmed Central Precocious Puberty will be randomized in a 1:1 ratio to receive a total of two (2) injections of either leuprolide acetate 11.25 mg or 30 mg depot formulation, each injection administered 3 months apart (6 months of treatment):

This study includes a Screening Period (up to 4 weeks), two 3-month treatment cycles, and a posttreatment follow-up period (12 weeks following the Month 6 visit). Study visits will occur at Screening, Day 1, Week 2 (only for subjects participating in the PK subset), Months 1, 2, 3, Month 6/Early Termination, and 12 weeks later, for the Posttreatment Follow-up Visit.

Study Design

Allocation: Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Puberty, Precocious

Intervention

Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg

Location

Birmingham
Alabama
United States
35233

Status

Completed

Source

Abbott

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

An enzyme that catalyzes the conversion of acetate esters and water to alcohols and acetate. EC 3.1.1.6.

Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general. It also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (From Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

A 6-methyl PROGESTERONE acetate with reported glucocorticoid activity and effect on ESTRUS.

An enzyme that catalyzes the formation of CoA derivatives from ATP, acetate, and CoA to form AMP, pyrophosphate, and acetyl CoA. It acts also on propionates and acrylates. EC 6.2.1.1.

An enzyme that catalyzes reversibly the phosphorylation of acetate in the presence of a divalent cation and ATP with the formation of acetylphosphate and ADP. It is important in the glycolysis process. EC 2.7.2.1.

Clinical Trials [407 Associated Clinical Trials listed on BioPortfolio]

Study of Lupron Depot In The Treatment of Central Precocious Puberty

The purpose of this study is to determine if leuprolide acetate is safe and effective in treating children with Central Precocious Puberty, and to assess long term effects of leuprolide ac...

Safety Extension Study Of Lupron Depot In The Treatment Of Central Precocious Puberty

The purpose of this study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (12 months).

Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer

The purpose of this research study is to determine the effects of abiraterone acetate plus leuprolide acetate and prednisone versus leuprolide acetate alone on hormone levels in the blood...

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

Primary Objective : - The primary objective of the study is to compare progression-free survival (PSA progression after systemic treatment, radiologically or histologically docume...

A Study of Leuprolide 45 mg Formulation to Treat Prostate Cancer

The purpose of this study is to access the efficacy and safety of two new formulations of leuprolide acetate 45 mg 6-month depot formulations in treating patients with prostate cancer.

PubMed Articles [689 Associated PubMed Articles listed on BioPortfolio]

Progressive Central Puberty in a Toddler with Partial Androgen Insensitivity.

A male infant was diagnosed with partial androgen insensitivity caused by a novel mutation in the androgen receptor. At 3.5 months of age, he received 100 mg of testosterone intramuscularly over the c...

Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids.

Uterine fibroids are the most common benign tumors of the female genital tract. The management of symptomatic fibroids has traditionally been surgical; however, alternative pharmacological approaches...

Sex pheromone components of the European goat moth,Cossus cossus.

Female tip washings of the European goat moth,Cossus cossus L., were found to contain the following compounds that are structurally similar to known pheromone components of Lepidoptera (%): decyl acet...

Prospective Evaluation of Testosterone Fluctuations During a Transition of Therapy From Degarelix to Leuprolide in Patients on Androgen Deprivation Therapy.

To evaluate for a possible testosterone surge during transition of therapy from degarelix to leuprolide.

Sex pheromone of the tomato looper,Plusia chalcites (ESP).

Z-7-Dodecenyl acetate (A) andZ-9-tetradecenyl acetate (B), in a 5∶1 ratio, have been identified as sex pheromone components of femalePlusia chalcites. In addition, small amounts of dodecyl acetate,...

More From BioPortfolio on "A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty"

Search BioPortfolio:
Advertisement
Advertisement